Last reviewed · How we verify
D745 formulation I
D745 formulation I is a small molecule that targets the molecular target.
D745 formulation I is a small molecule that targets the molecular target. Used for Indication 1.
At a glance
| Generic name | D745 formulation I |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Target | molecular target |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action of D745 formulation I is not well understood, but it is believed to work by interacting with the molecular target, leading to a therapeutic effect.
Approved indications
- Indication 1
Common side effects
- Common adverse event
Key clinical trials
- The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D745 formulation I CI brief — competitive landscape report
- D745 formulation I updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI